Abstract: Journal Pre-proof COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial Nejla Stambouli , Adel Driss , Faten Gargouri , Khadija Bahrini , Bilel Arfaoui , Rim Abid , Karima Taamallah , Souha Hannachi , Sana Boughariou , Aicha Rebai , Imen Naas , Mohamed Ghanem , Hassib Ammar , Chiraz Aichaouia , Asma Harrathi , Mohamed Ali Yousfi , Riadh Battikh , Mohamed Ben Moussa , Rabie Razgallah , Mustapha Ferjani , Hédi Gharsallah , on behalf of the of “OD-doxy-PNV-COVID-19 Trial” PII: DOI: Reference: S1201-9712(22)00349-6 https://doi.org/10.1016/j.ijid.2022.06.016 IJID 6251 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 2 March 2022 26 April 2022 13 June 2022 Please cite this article as: Nejla Stambouli , Adel Driss , Faten Gargouri , Khadija Bahrini , Bilel Arfaoui , Rim Abid , Karima Taamallah , Souha Hannachi , Sana Boughariou , Aicha Rebai , Imen Naas , Mohamed Ghanem , Hassib Ammar , Chiraz Aichaouia , Asma Harrathi , Mohamed Ali Yousfi , Riadh Battikh , Mohamed Ben Moussa , Rabie Razgallah , Mustapha Ferjani , Hédi Gharsallah , on behalf of the of “OD-doxy-PNV-COVID-19 Trial”, COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.06.016 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Research highlights     Using Doxycycline and Zinc as a potential treatment in SARS-COV-2 infection. SARS-CoV-2 contamination appeared to be reduced after treatment. COVID-19 infection risk was not associated with other comorbidities. The combined treatments of Doxycycline and Zinc have minimal side effects. 1 COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial Nejla Stambouli1,11, Adel Driss2, Faten Gargouri1,§, Khadija Bahrini11,§, Bilel Arfaoui3,§,*, Rim Abid4,§,*, Karima Taamallah8,*, Souha Hannachi4,§,*, Sana Boughariou5,*, Aicha Rebai5,*, Imen Naas5,*, Mohamed Ghanem6,*, Hassib Ammar1, Chiraz Aichaouia7,*, Asma Harrathi1, Mohamed Ali Yousfi9,§, Riadh Battikh4,§,*, Mohamed Ben Moussa10,§, Rabie Razgallah11, Mustapha Ferjani1,§,*, Hédi Gharsallah5,11,§,* on behalf of the of ―OD-doxyPNV-COVID-19 Trial‖†. 1 General Directorate of Military Health 2 Department of Physiology, Morehouse School of Medicine, Atlanta GA, USA. 3 Department of Internal Medicine 4 Department of Infectious Disease 5 Department of Intensive Care 6 Department of Gastroenterology 7 Department of Pneumology 8 Department of cardiology 9 Department of Pharmacy 10 Laboratory of..